HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Richard E. Clark Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Deboer, D. A. Articles by Clark, R. E. Search for Related Content PubMed PubMed Citation Articles by Deboer, D. A. Articles by Clark, R. E.

Ann Thorac Surg 1992;53:412-418
© 1992 The Society of Thoracic Surgeons

---

Articles

Iron chelation in myocardial preservation after ischemia-reperfusion injury: The importance of pretreatment and toxicity

Surgery Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland USA

Accepted for publication August 13, 1991.

^_* Address reprint requests to Dr Clark, Cardiovascular/Pulmonary Research Center, Allegheny-Singer Research Institute, 320 East North Ave, Pittsburgh, PA 15212-9986 USA.

Oxygen-derived free radicals have been implicated in myocardial ischemia-reperfusion injury. It has been proposed that deferoxamine, an iron chelator, improves myocardial preservation by reducing the iron-catalyzed production of the hydroxyl radical. The objectives of this study were to define the appropriate timing of iron chelation therapy and the dose-response properties of deferoxamine. Isolated working rat hearts were subjected to 25 minutes of normothermic global ischemia. Deferoxamine was given as pretreatment (n = 39; doses of 10 or 30 mg/kg), added to cardioplegic solution (n = 43; doses 0.46 to 1.90 mmol/L), or administered upon reperfusion (n = 52; doses 0.15 to 0.76 mmol/L) and compared with saline controls (n = 25), Deferoxamine pretreatment improved survival at each dose from a control value of 44% to 71% and 72% (p < 0.05), respectively. A cardioplegia dose of 0.46 mmol/L improved survival from 48% to 75%. Higher doses reduced survival and implied a toxic effect. Reperfusion therapy did not alter survival. Regardless of time of administration, deferoxamine did not improve ventricular function or adenosine triphosphate levels. Deferoxamine given as pretreatment 1 hour before ischemia at doses of 30 mg/kg, and perhaps as low as 10 mg/kg, significantly improved survival. The addition of deferoxamine to cardioplegic solution was safe and may be protective at approximately 0.50 mmol/L; however, toxicity should be considered at concentrations greater than 0.76 mmol/L. These data support the postulate that iron catalysis is involved in the production of oxygen-derived free radicals during ischemia-reperfusion injury. We conclude that pretreatment before ischemia is an important component of iron chelation therapy in myocardial preservation.

This article has been cited by other articles:

				K. Wu, T. R. Turk, U. Rauen, S. Su, T. Feldkamp, H. de Groot, I. Wiswedel, H. A. Baba, A. Kribben, and O. Witzke Prolonged cold storage using a new histidine-tryptophan-ketoglutarate-based preservation solution in isogeneic cardiac mouse grafts Eur. Heart J., February 2, 2011; 32(4): 509 - 516. [Abstract] [Full Text] [PDF]

				I. A. Paraskevaidis, E. K. Iliodromitis, D. Vlahakos, D. P. Tsiapras, A. Nikolaidis, A. Marathias, A. Michalis, and D. Th. Kremastinos Deferoxamine infusion during coronary artery bypass grafting ameliorates lipid peroxidation and protects the myocardium against reperfusion injury: immediate and long-term significance Eur. Heart J., February 1, 2005; 26(3): 263 - 270. [Abstract] [Full Text] [PDF]

				A. K. Salahudeen Cold ischemic injury of transplanted kidneys: new insights from experimental studies Am J Physiol Renal Physiol, August 1, 2004; 287(2): F181 - F187. [Abstract] [Full Text] [PDF]

				Z. S. Jonjev, D. W. Schwertz, J. M. Beck, J. D. Ross, and W. R. Law Subcellular distribution of protein kinase C isozymes during cardioplegic arrest J. Thorac. Cardiovasc. Surg., December 1, 2003; 126(6): 1880 - 1885. [Abstract] [Full Text] [PDF]

				B. de Valk and J. J. M. Marx Iron, Atherosclerosis, and Ischemic Heart Disease Arch Intern Med, July 26, 1999; 159(14): 1542 - 1548. [Abstract] [Full Text] [PDF]

				S. C. Nicholson, M. Squier, D. J. P. Ferguson, Z. Nagy, S. Westaby, and R. D. Evans Effect of Desferrioxamine Cardioplegia on Ischemia-Reperfusion Injury in Isolated Rat Heart Ann. Thorac. Surg., April 1, 1997; 63(4): 1003 - 1011. [Abstract] [Full Text]

				G. Drossos, A. Lazou, P. Panagopoulos, and S. Westaby Deferoxamine cardioplegia reduces superoxide radical production in human myocardium Ann. Thorac. Surg., January 1, 1995; 59(1): 169 - 172. [Abstract] [PDF]

				V. E. Whitehurst, X. Joseph, F. R. Alleva, J. A. Vick, P. Whittaker, J. Zhang, B. E. Fry Jr., and T. Balazs Enhancement of Acute Myocardial Lesions by Asthma Drugs in Rats Toxicol Pathol, January 1, 1994; 22(1): 72 - 76. [Abstract] [PDF]